Posters/Publications

Title
Venue
Type
Date

ASC43F Tablet as a One pill, Once a day Fixed dose Combination of ASC41 a THR-β Agonist, and ASC42 a FXR Agonist, Demonstrated Comparable Dissolution Profiles and in vivo Pharmacokinetics VS Single ASC41 and ASC42 Tablets

The Liver Meeting® 2021 of the American Association for the Study of Liver Diseases (AASLD)

Poster

11/2021
ASC42, a Novel Non-steroidal FXR Agonist, Demonstrates a Normal Cholesterol Profile and Lack of Pruritus at Therapeutic Doses in a 14-day Phase I Randomized, Double-blind, Placebo Controlled Study in Healthy Volunteers

The Liver Meeting® 2021 of the American Association for the Study of Liver Diseases (AASLD)

Poster

11/2021
A Phase Ib Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ASC 41 a THR-β Agonist, for 28-days in Overweight and Obese Subjects with Elevated LDL-C, a Population with Characteristic s Of NAFLD

The Liver Meeting® 2021 of the American Association for the Study of Liver Diseases (AASLD)

Poster

11/2021